LRRC4 and rosacea: By utilizing an antagonist peptide of VIP receptor, VIPhyb34,35, we found that inhibition of VIP signaling could greatly improve rosacea-like dermatitis in Lrrc4 mutant mice compared with the mice treated with scrambled VIPhyp peptides (sVIPhyp) (Fig. 6e, f).